Spherix Global Insights’ Quarterly Update on the US Migraine Prevention Market Reveals Best-In-Class Sales and Medical Affairs Support as the Driving Force Behind Teva’s Ajovy Early Launch Success

EXTON, Pa.: With the 2018 launches of the new class of anti-calcitonin gene-related peptide (CGRP) therapies, specifically Amgen/Novartis’ Aimovig, Teva’s Ajovy, and Eli Lilly’s Emgality, for the prevention of migraine
error: Content is protected !!